Lupin’s arm recalling over 6 lakh bottles of Ramipril capsules in US

26 Nov 2024 Evaluate

Lupin’s arm -- Lupin Pharmaceuticals Inc. is recalling 6,16,506 bottles of Ramipril capsules, a medication indicated for high blood pressure in the US due to deviation from current good manufacturing practices (CGMP). The company is recalling 1,12,770 bottles of 2.5 mg tablets; 1,46,322 bottles of 5 mg tablets and 3,57,414 bottles of 10 mg tablets. The affected lot is manufactured at Lupin's Goa-based manufacturing facility. 

The company is undertaking Class II voluntary recall due to CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor. As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×